Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1

Conditions

Carcinoma, Non-Small-Cell Lung 299Lung Neoplasms 107Pancreatic Neoplasms 69Neoplasms 53Neoplasm Metastasis 31Brain Neoplasms 31Head and Neck Neoplasms 26Squamous Cell Carcinoma of Head and Neck 25Breast Neoplasms 25Glioblastoma 24Adenocarcinoma of Lung 23Gliosarcoma 22Non-Squamous Non-Small Cell Lung Cancer 18Colorectal Neoplasms 18Carcinoma, Hepatocellular 17Adenocarcinoma, Bronchiolo-Alveolar 16Rectal Neoplasms 13Colonic Neoplasms 13Carcinoma, Renal Cell 13Glioma 12Esophageal Neoplasms 11Astrocytoma 11Central Nervous System Neoplasms 9Carcinoma, Squamous Cell 9Salivary Gland Neoplasms 8Prostatic Neoplasms 8Oligodendroglioma 8Gallbladder Neoplasms 8Adenocarcinoma 8Ovarian Neoplasms 7

Interventions

Sorafenib 3pazopanib 2Sunitinib 2verubulin 1trifluridine tipiracil drug combination 1irinotecan sucrosofate 1eribulin 1Valproic Acid 1Temozolomide 1Sirolimus 1Irinotecan 1Interleukin-27 1Hydralazine 1Erlotinib Hydrochloride 1Azurin 1Arsenic Trioxide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Refractory Solid Tumors × Erlotinib Hydrochloride × Clear all
NCT00759928 2014-07-02

PK Trial of Sorafenib & Erlotinib in Patients With Refractory Solid Tumors

SCRI Development Innovations, LLC

Phase 1 Completed
48 enrolled
Other solid neoplasm

Refractory Solid Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡